Skip to main content
. Author manuscript; available in PMC: 2019 Oct 10.
Published in final edited form as: Cell Host Microbe. 2018 Oct 10;24(4):487–499.e5. doi: 10.1016/j.chom.2018.09.008

Figure 5.

Figure 5.

Prevention from in utero transmission of ZIKV in pregnant mice. (a) Experimental design. Three-week-old female A129 mice were subcutaneously inoculated with 105 FFU of C7a/t (n=8) or DPBS (sham; n=6). (b) Viremia post-immunization. The viremia was measured on BHK-HA-C cells. (c) Neutralizing antibodies in serum on day 28 post-immunization and E10.5 during pregnancy. (d) Maternal viremia at E12.5 after ZIKV challenge. The pregnant mice were challenged at E10.5 with 106 PFU of ZIKV PRVABC59. (e) Viral loads in maternal organs at E18.5. (f) Viral loads in placenta at E18.5. (g) Viral loads in fetal heads at E18.5. (h) Fetal weight at E18.5. (i) Neutralizing antibodies in fetal serum. Viremia was determined by plaque assay. The NT50s were determined by an mCherry ZIKV neutralization assay. An unpaired nonparametric Mann-Whitney test was used for analyzing statistical significance. The L.O.D.s for viremia, tissue virus load, maternal NT50s, and fetal NT50s are 100 FFU/ml, 100 PFU/g tissue, 100 dilution, and 10 dilution, respectively.